Verrica Pharmaceuticals Announces Presentation at the Jefferies Global Healthcare Conference in London

November 10, 2023 7:30am

WEST CHESTER, PA – Nov. 10, 2023 (GLOBE NEWSWIRE) – Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases requiring medical interventions, today announced Ted White, Verrica President & Chief Executive Officer, will present at the upcoming Jefferies Global Healthcare Conference, which is being held in London from November 14-16, 2023.


Event details:

Date: Wednesday, November 15, 2023

Time: 2:00 pm GMT

Location: London, UK

Participants may access a live webcast of the event by clicking the link here.


The webcast can also be accessed in the Investors/Presentations & Events section of the Verrica website at A replay of the webcast will be posted shortly after the presentation and will be available for 90 days following the event.


About Verrica Pharmaceuticals Inc.

Verrica is a dermatology therapeutics company developing medications for skin diseases requiring medical interventions. On July 21, 2023, Verrica’s lead product, YCANTH™ (cantharidin), became the first treatment approved by the FDA to treat pediatric and adult patients with molluscum contagiosum, a highly contagious viral skin infection affecting approximately 6 million people in the United States, primarily children. VP-102 is also in development to treat common warts and external genital warts, two of the largest unmet needs in medical dermatology. Verrica is developing VP-103, its second cantharidin-based product candidate, for the treatment of plantar warts. Verrica has also entered a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for dermatologic oncology conditions. For more information, visit



Terry Kohler 
Chief Financial Officer

Kevin Gardner
LifeSci Advisors

Chris Calabrese
LifeSci Advisors